Novartis Pharma: The Business Unit Model

Srikant M. Datar; Carin-Isabel  Knoop; Cate  Reavis

Case | HBS Case Collection | January 2001 (Revised May 2003)

Novartis Pharma: The Business Unit Model

by Srikant M. Datar, Carin-Isabel Knoop and Cate Reavis

Abstract

In June 2000, Novartis reorganized its pharmaceutical business to form global business units in oncology, transplantation, ophthalmology, and mature products. The remaining primary care products continued to be managed within global functions (e.g., R&D and marketing). The new organization created a matrix structure and new roles and responsibilities for heads of business functions, CEOs of new business units, and country managers operating in over 100 countries.

Keywords: Restructuring; Recruitment; Product Marketing; Organizational Structure; Problems and Challenges; Health Industry; Pharmaceutical Industry;

Language: English

Format: Print

21 pages

Educators Purchase

Citation:

Datar, Srikant M., Carin-Isabel Knoop, and Cate Reavis. "Novartis Pharma: The Business Unit Model." Harvard Business School Case 101-030, January 2001. (Revised May 2003.)

Dr. Varda Shalev bridges technology and medicine through Maccabitech, a “research and innovation wing” of Israel’s Maccabi Healthcare Services (MHS) that partners with research institutions, pharmaceutical companies, and startups. Shalev hopes to scale Maccabitech's efforts through the creation of a platform that will enable external researchers to access MHS data. Yet it is unclear how best to structure the platform and its policies. How can Maccabitech maximize impact while still creating value for MHS? And what risks does Maccabitech need to manage?

We describe how Coronary Artery Bypass Grafting (CABG, or more popularly, “bypass”) operations revolutionized the treatment of coronary disease (that can produce fatal heart attacks and debilitating angina). Specifically we chronicle the 1) development of the foundational procedures and technologies that provided a base for CABG; 2) early CABG operations performed in the 1960s; 3) rapid—and controversial growth—that occurred in the U.S. in the 1970s and; 4) emergence and rapid diffusion of the less invasive angioplasty alternative that slowed the growth of CABG in the last two decades of the 20th century.

We describe how Computed Tomography (CT) scanners—that combine x-rays and computers to image soft tissues of the brain and other organs—have become a widely used diagnostic tool. Specifically, we chronicle the following: 1) development of the first CT scanner (through the early 1970s); 2) rapid and enthusiastic adoption of CT scanning (until the late 1970s); 3) regulatory backlash against the perceived overuse of this expensive technology (in the 1980s); and 4) innovations that reignited growth (in the 1990s and 2000s).

Faculty & Research

Novartis Pharma: The Business Unit Model

Abstract

Citation:

About the Author

More from the Author